| Prostate MRI and transperineal TRUS/MRI fusion biopsy for prostate cancer detection: clinical practice updates | Eugenio MARTORANA,Giacomo Maria PIROLA,Maria Cristina AİSA,Pietro SCİALPİ,Aldo Di BLASI,Giovanni SAREDI,Alfredo D'ANDREA,Stefano SIGNORE,Riccardo GRISANTI,Michele SCİALPİ | 237–244 |
| Implications of the Fracture Risk Assessment Algorithm for the assessment and improvement of bone health in patients with prostate cancer: A comprehensive review | Ashish SHARMA,Rahul Janak SİNHA,Vishwajeet SINGH,Gaurav GARG,Samarth AGARWAL,Siddharth PANDEY | 245–253 |
| A comparison between the efficacy and safety of microscopic inguinal and subinguinal varicocelectomy | Şaban Oğuz DEMİRDÖĞEN,FATİH ÖZKAYA,Ahmet Emre CİNİSLİOĞLU,Mehmet Sefa ALTAY,Şenol ADANUR,ÖZKAN POLAT,İSA ÖZBEY | 254–260 |
| Is active surveillance an appropriate approach to manage prostate cancer patients with Gleason Score 3+3 who met the criteria for active surveillance? | Saleh GHIASY,Amir Reza ABEDI,Afshin MORADI,Seyed Yousef HOSSEINI,Morteza Fallah KARKAN,Ghazal SADRI,Mohammadreza DAVARI | 261–264 |
| Robotic-assisted perineal versus transperitoneal radical prostatectomy: A matched-pair analysis | Volkan TUĞCU,OKTAY AKÇA,Abdülmüttalip ŞİMŞEK,İsmail YİĞİTBAŞI,SELÇUK ŞAHİN,Mustafa Gürkan YENİCE,ALİ İHSAN TAŞÇI | 265–272 |
| Prognostic significance of tumor budding in muscle invasive urothelial carcinomas of the bladder | ÜLKÜ KÜÇÜK,Sümeyye EKMEKÇİ,Ebru ÇAKIR,Zübeyde EKİN,Batuhan ERGANİ,Gökhan Rahmi EKİN | 273–278 |
| Brain metastases from prostate cancer: A single-center experience | GÜL KANYILMAZ,MERYEM AKTAN,BERRİN BENLİ YAVUZ,MEHMET KOÇ | 279–283 |
| Artificial urinary sphincter revision with Quick Connects® versus suture−tie connectors: does technique make a difference? | Jack R. ANDREWS,Brian J. LINDER,Joseph A. SCALES,Daniel S. Elliott | 284–288 |
| The effect of α-and δ-tocopherol-lipoic acid ester co-drugs on the response of the rabbit bladder to in vitro ischemia/reperfusion | Robert M. LEVIN,Catherine SCHULER,Robert E. LEGGETT,Martha A. HASS | 289–295 |
| Safety and efficacy of Intravesical hyaluronic acid/chondroitin sulfate in the treatment of refractory painful bladder syndrome |